Tags

Type your tag names separated by a space and hit enter

Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
J Psychopharmacol. 2009 May; 23(3):305-14.JP

Abstract

Patients suffering from schizophrenic psychoses sometimes insufficiently respond to antipsychotic monotherapy and then combination approaches are preferred. We aimed in validating the add-on of ziprasidone and risperidone to clozapine, and we performed a randomised head-to-head trial. Patients with partial response to clozapine were randomly attributed to augmentation with ziprasidone (n = 12) or risperidone (n = 12). Efficacy assessments included the Positive and Negative Syndrome Scale (PANSS), the Scale for the Assessment of Negative Symptoms (SANS), the Hamilton Depression Scale (HAMD), the Clinical Global Impression (CGI) and the Global Assessment of Functioning (GAF). Furthermore, several safety and tolerability measures were obtained. After six weeks, both groups showed significant reductions of positive and negative symptoms. In addition, affective state, psychosocial functioning and clozapine side effects improved without significant differences between the groups. Both approaches were well tolerated. However, the ziprasidone group experienced a small elongation of the QTc interval and a reduction of extrapyramidal symptoms. Patients under clozapine-risperidone therapy developed a rise of serum prolactin levels. The clozapine augmentation with ziprasidone or risperidone resulted in significant psychopathological improvements. The side effects differed between the treatment groups. Further head-to-head comparisons of atypical antipsychotics as add-on to clozapine are necessary.

Authors+Show Affiliations

Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany. mathias.zink@zi-mannheim.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18562423

Citation

Zink, Mathias, et al. "Efficacy and Tolerability of Ziprasidone Versus Risperidone as Augmentation in Patients Partially Responsive to Clozapine: a Randomised Controlled Clinical Trial." Journal of Psychopharmacology (Oxford, England), vol. 23, no. 3, 2009, pp. 305-14.
Zink M, Kuwilsky A, Krumm B, et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol. 2009;23(3):305-14.
Zink, M., Kuwilsky, A., Krumm, B., & Dressing, H. (2009). Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. Journal of Psychopharmacology (Oxford, England), 23(3), 305-14. https://doi.org/10.1177/0269881108089593
Zink M, et al. Efficacy and Tolerability of Ziprasidone Versus Risperidone as Augmentation in Patients Partially Responsive to Clozapine: a Randomised Controlled Clinical Trial. J Psychopharmacol. 2009;23(3):305-14. PubMed PMID: 18562423.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. AU - Zink,Mathias, AU - Kuwilsky,A, AU - Krumm,B, AU - Dressing,H, Y1 - 2008/06/18/ PY - 2008/6/20/pubmed PY - 2009/7/10/medline PY - 2008/6/20/entrez SP - 305 EP - 14 JF - Journal of psychopharmacology (Oxford, England) JO - J Psychopharmacol VL - 23 IS - 3 N2 - Patients suffering from schizophrenic psychoses sometimes insufficiently respond to antipsychotic monotherapy and then combination approaches are preferred. We aimed in validating the add-on of ziprasidone and risperidone to clozapine, and we performed a randomised head-to-head trial. Patients with partial response to clozapine were randomly attributed to augmentation with ziprasidone (n = 12) or risperidone (n = 12). Efficacy assessments included the Positive and Negative Syndrome Scale (PANSS), the Scale for the Assessment of Negative Symptoms (SANS), the Hamilton Depression Scale (HAMD), the Clinical Global Impression (CGI) and the Global Assessment of Functioning (GAF). Furthermore, several safety and tolerability measures were obtained. After six weeks, both groups showed significant reductions of positive and negative symptoms. In addition, affective state, psychosocial functioning and clozapine side effects improved without significant differences between the groups. Both approaches were well tolerated. However, the ziprasidone group experienced a small elongation of the QTc interval and a reduction of extrapyramidal symptoms. Patients under clozapine-risperidone therapy developed a rise of serum prolactin levels. The clozapine augmentation with ziprasidone or risperidone resulted in significant psychopathological improvements. The side effects differed between the treatment groups. Further head-to-head comparisons of atypical antipsychotics as add-on to clozapine are necessary. SN - 0269-8811 UR - https://www.unboundmedicine.com/medline/citation/18562423/Efficacy_and_tolerability_of_ziprasidone_versus_risperidone_as_augmentation_in_patients_partially_responsive_to_clozapine:_a_randomised_controlled_clinical_trial_ L2 - https://journals.sagepub.com/doi/10.1177/0269881108089593?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -